Fig. 1From: Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapyStudy flow diagram. ICI, immune checkpoint inhibitor; irAEs, immune-related adverse eventsBack to article page